<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049634</url>
  </required_header>
  <id_info>
    <org_study_id>1628.00</org_study_id>
    <secondary_id>FHCRC-1628.00</secondary_id>
    <secondary_id>NCI-H02-0099</secondary_id>
    <secondary_id>CDR0000258137</secondary_id>
    <nct_id>NCT00049634</nct_id>
  </id_info>
  <brief_title>Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder</brief_title>
  <official_title>A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs before a donor peripheral blood stem cell transplant&#xD;
      helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system&#xD;
      from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused&#xD;
      into the patient they may help the patient's bone marrow make stem cells, red blood cells,&#xD;
      white blood cells, and platelets. Giving colony-stimulating factors, such as G-CSF, to the&#xD;
      donor helps the stem cells move from the bone marrow to the blood so they can be collected&#xD;
      and stored.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying how well donor peripheral stem cell transplant&#xD;
      works in treating patients with myelodysplastic syndrome, acute myeloid leukemia, or&#xD;
      myeloproliferative disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the incidence of grades II, III, and IV graft-vs-host disease (GVHD) in&#xD;
           patients with myelodysplastic syndromes (MDS), acute myeloid leukemia transformed from&#xD;
           MDS, or myeloproliferative disorders treated with immunologically engineered, filgrastim&#xD;
           (G-CSF)-mobilized, allogeneic peripheral blood stem cell transplantation.&#xD;
&#xD;
        -  Determine the incidence of graft failure, relapse, and transplant-related mortality by&#xD;
           day 100 in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of chronic GVHD, in terms of number and duration of&#xD;
           immunosuppressant therapies, in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the feasibility of partial T-cell depletion in G-CSF-mobilized peripheral&#xD;
           blood stem cells.&#xD;
&#xD;
      OUTLINE: Patients receive conditioning with oral busulfan every 6 hours on days -7 to -4 and&#xD;
      cyclophosphamide IV on days -3 and -2. Immunologically engineered, filgrastim&#xD;
      (G-CSF)-mobilized, allogeneic peripheral blood stem cells are infused on day 0.&#xD;
&#xD;
      Patients receive graft-vs-host disease prophylaxis comprising methotrexate IV on days 1, 3,&#xD;
      6, and 11 and cyclosporine IV over 1-4 hours (orally twice daily when tolerated) on days -1&#xD;
      to 80 and then gradually tapered over 5 months beginning on day 81.&#xD;
&#xD;
      Patients are followed regularly through day 100 and then at 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade II, III, and IV graft-versus-host disease</measure>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  Myelodysplastic syndromes (MDS) that has advanced beyond refractory anemia (RA)&#xD;
&#xD;
               -  RA with excess blasts (RAEB) (greater than 5% blasts)&#xD;
&#xD;
               -  RAEB in transformation (greater than 20% but less than 30% blasts)&#xD;
&#xD;
               -  Acute myeloid leukemia (greater than 30% blasts) that evolved from MDS&#xD;
&#xD;
               -  Myeloproliferative disorder, including chronic myelomonocytic leukemia, agnogenic&#xD;
                  myeloid metaplasia, polycythemia vera, or essential thrombosis&#xD;
&#xD;
          -  No chronic myelogenous leukemia with or without excess (greater than 5%) blasts&#xD;
&#xD;
          -  Must have an HLA-identical, related donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 2 times upper limit of normal (ULN)*&#xD;
&#xD;
          -  SGOT/SGPT less than 2 times ULN* NOTE: * Unless due to malignancy&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL OR&#xD;
&#xD;
          -  Glomerular filtration rate at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Cardiac ejection fraction at least 45%&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO at least 60% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Human antimouse antibody negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
          -  No hypersensitivity to cyclosporine&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior marrow transplantation&#xD;
&#xD;
          -  No concurrent growth factors for 21 days after study transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann E. Woolfrey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ann E. Woolfrey</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

